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Background. Probiotic oral intake, via modulation of the microbiota-gut-brain axis, can impact brain activity, mood, and behavior;
therefore, it may be beneficial against psychological distress and anxiety disorders. Inflammatory cytokines can influence the onset
and progression of several neurodegenerative mood disorders, and the IL-1β rs16944 SNP is related to high cytokine levels and
potentially affects mood disorders. The aim of this study was to examine the combined effect of IL-1β polymorphism and
probiotic administration in mood disorder phenotypes in the Italian population.Methods. 150 subjects were randomized into two
different groups, probiotic oral suspension group (POSG) and placebo control group (PCG), and received the relative treatment
for 12 weeks. Psychological profile assessment by Hamilton Anxiety Rating Scale (HAM-A), Body Uneasiness Test (BUT), and
Symptom Checklist 90-Revised (SCL90R) was administered to all volunteers. Genotyping was performed on DNA extracted from
salivary samples. Results. After 12 weeks of intervention, a significant reduction of HAM-A total score was detected in the POSG
(p < 0:01), compared to the PCG. Furthermore, IL-1β carriers have moderate risk to develop anxiety (OR = 5:90), and in POSG
IL-1β carriers, we observed a reduction of HAM-A score (p = 0:02). Conclusions. Consumption of probiotics mitigates anxiety
symptoms, especially in healthy adults with the minor A allele of rs16944 as a risk factor. Our results encourage the use of
probiotics in anxiety disorders and suggest genetic association studies for psychobiotic-personalized therapy.
1. Introduction
In the last years, the increased scientific interest about
microbiota and its relationship with health maintenance
and disease onset underlined the importance of bacterial
composition in the gastrointestinal tract. In the neuroscience
field, the recognized complex bidirectional communication
between host microbiota and brain-gut axis opened to new
discoveries on the neurological disorders and disease onset
and tailored treatments for affected patients.
Two neuroanatomical pathways are involved in the
brain-gut interaction. The central nervous system (CNS)
shares information with the lumen and the enteric nervous
system (ENS) [1], through the sympathetic and parasym-
pathetic branches of the autonomic nervous system
(ANS), and they mutually modulate gut functions and
environment [2, 3].
Secondly, psychophysical stress can set off adaptive pro-
cesses by the neuroendocrine system, which in turn regulates
the hypothalamic-pituitary-adrenal (HPA) axis, increasing
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the levels of inflammatory cytokines and prostaglandins in
the gut. These events lead to changes in the microbiota com-
position and increased gastrointestinal permeability [4].
HPA axis activity influences physiological and behavioral
states, including anxiety and depressive disorders [5]. A bal-
anced microbiota-gut-brain (MGB) axis improves CNS and
ENS functions [4–6]. Conversely, MGB axis impairment
damages gut microbiota, destroys intestinal epithelium
integrity, and affects permeability, increasing circulating
levels of endotoxin, bacterial lipopolysaccharide (LPS), and
inflammatory mediators [7]. Currently, it is well known that
intestinal inflammation and gut microbiota imbalance are
related to chronic abdominal pain syndromes and eating dis-
orders, and increasing evidences highlighted a link between
gut microbiota and neurological and psychiatric disorders,
such as anxiety and depression [8, 9].
Anxiety is a feeling characterized by agitation, anguish,
fear, and disproportionate worry, usually without triggers,
accompanied by various somatic signs [10]. This disturbance
is related to different adverse health outcomes, especially in
the elderly [11].
In vivo studies observed the development of anxiety signs
and symptoms after fecal microbiota transplants, highlight-
ing the ability to affect neuropsychiatric conditions through
the changes of the microbial composition [12]. Although
these effects were observed also in germ-free mice [13], this
suggests to use probiotics as a treatment in neuropsychiatric
disorders.
For this purpose, Lactobacillus, Bifidobacterium, and
others species were used in animal and human studies as pro-
biotic supplements to enhance the biodiversity and health of
the gut microbiota [14] and to treat anxiety disorders,
through the improvement of the MGB axis balance [15],
obtaining the title “psychobiotics.”
Interleukin-1 beta (IL-1β) was clearly identified as an
important player in the onset and progression of several neu-
rodegenerative diseases [16], and numerous studies have
already proved the link between mood disorder symptoms
and proinflammatory cytokine expression and circulating
levels [17].
Psychophysical stress increases the proinflammatory
cytokines through the HPA axis, impairing the gut barrier
integrity and causing dysbiosis related to anxiety disorder
[18–21]. In particular, IL-1β, after a psychophysiological
stress stimulus, can affect the gut microbiota balance and
mood status [22]. The IL-1β expression is strongly influ-
enced by some polymorphisms in the IL-1β gene, which
increase the related cytokine levels, thus affecting the magni-
tude of inflammatory disorders, making them a determining
cofactor in several chronic diseases and potentially in the
onset mood disorders [23].
In particular, increased levels of IL-1β were observed
in the presence of the rs16944 polymorphism (NM_
0000576.2:c.-598T>C), which is found in the promoter
region of IL-1β [24]. The rs16944 is located in the func-
tional promoter region (https://www.ncbi.nlm.nih.gov/
variation/tools/1000genomes/). The presence of the allele
A of rs16944 increases the IL-1β production, and it was
associated with elevated risk of depression in schizo-
phrenic spectrum disorders [25], depressive symptoms in
Alzheimer disease [26, 27], and depressed state in breast
cancer patients [28]. The relationship between IL-1β poly-
morphism and anxiety disorder was observed by Kovacs
et al. [29], but no other study has investigated the com-
bined effect of IL-1β polymorphism and probiotic admin-
istration in mood disorder phenotypes.
Therefore, in the present study, we investigated if the
administration of psychobiotic suspension could represent
a novel, safe, and long-term solution to treat or prevent anx-
iety disorders, to reduce associated symptoms, and to amelio-
rate their psychological state, in carriers of IL-1β rs16944
gene polymorphism. To this end, a randomized, placebo-
controlled clinical trial was conducted on female and male
volunteers.
In this study, the primary objective was to investigate
the effects of the SNP rs16944 within the IL-1β gene on
anxiety development in a sample of the Italian population.
The secondary outcome was to evaluate the possible bene-
ficial effect of a new probiotic formulation on anxiety and
related symptoms according to the IL-1β SNP rs16944.
The third objective was to assess a change in body shape
perception before and after probiotic intervention. To this
end, a randomized, placebo-controlled clinical trial was
conducted on volunteers.
2. Materials and Methods
2.1. Study Design and Outcomes. The study protocol was
conducted between January 2017 and July 2017, using an
interventional randomized placebo-controlled clinical trial.
At the time of recruitment, the patients were submitted to
nutritional status and psychometric test evaluation. A medi-
cal history was performed and saliva samples were collected.
The subjects received the psychobiotic mixture or the placebo
at the beginning of the trial with consumption instructions.
Volunteers consumed the relative treatments at home, once
daily (1 sachet/day), two hours before lunch, in order to
ensure adequate gastrointestinal transit and absorption.
Eligible patients were randomly divided into two groups:
(1) psychobiotic oral suspension group (POSG) and (2)
placebo control group (PCG).
Both groups followed the assigned treatment for a 12-
week period. The subjects were asked to maintain their usual
lifestyle and dietary habits and to report any illness or adverse
reaction emerging during study conduction. The subjects
were asked to report any missed consumption of the prod-
ucts during the intervention. The POSG and PCG arms were
double-blinded. The subjects repeated nutritional visit 12
weeks after intervention initiation of each arm (±3 days).
Nutritional status evaluation, psychometric tests, and
buccal mucosa sample extraction were carried out at the time
of enrollment (T0) and after the 12-week period intervention
(T1). All participants recruited into the study authorized
their participation by reading and signing the informed
consent form, drafted in accordance to the provisions of the
Ethics Committee of Medicine, University of Rome “Tor
Vergata,” and with the Helsinki Declaration of 1975, as
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revised in 1983. Trial registration: this protocol has been reg-
istered with ClinicalTrials.gov Id: NCT01890070.
2.2. Subjects. 150 volunteers were initially recruited during
routine medical check-up visits at the Section of Biomedicine
and Prevention, Division of Clinical Nutrition and Nutri-
genomics of the University of Rome “Tor Vergata.” Exclu-
sion criteria were age < 18 and >65, pregnant and lactating
women, type 1 diabetes, established altered intestinal
bacterial flora (intestinal bacterial overgrowth), history of
psychiatric or psychological disturbance, absence of
depression evaluated with Symptom Checklist-90 (SCL90)
Global Severity Index (GSI) (score < 1), acute disease,
endocrine, metabolic, liver, and gastrointestinal disease,
cardiovascular or kidney dysfunction, cancer, and HIV
infection. Subjects that were recently under antibiotic
treatments, chronic pharmacological therapy with anti-
inflammatory drugs or oral contraceptives, other probiotics
or dietary supplements, subjects who are following dietary
treatments, smokers, and alcohol and drug abusers were
also excluded from the protocol. No subjects with known
alterations of intestinal transit following organic patholo-
gies (abdominal surgery, diabetes mellitus, scleroderma,
hypothyroidism, etc.) were included in the study. The sub-
jects enrolled into the study were asked to not consume
any other probiotics or food supplements for the whole
duration of the study.
2.3. Interleukin 1 Beta Genotyping. The DNA extraction from
salivary samples collected with swabs was performed accord-
ing to Hochmeister et al. [30]. gDNA was quantified with
NanoDrop. Master Mix Taq DNA Polymerase and dNTPs
(TaqPath ProAmp Master Mix, Life Technologies, CA,
USA) and a two allele-specific fluorescent probes (TaqMan
SNP Genotyping Assays, Life Technologies, CA, USA) were
used to prepare the gDNA for the genotyping. The IL-1β
gene rs16944 (NM_0000576.2:c.-598T>C) context sequence
was as follows: TACCTTGGGTGCTGTTCTCTGCCT
C(G/A)GGAGCTCTCTGTCAATTGCAGGAGC.
Genotyping was carried out using the StepOnePlus™
Real-Time PCR System (Applied Biosystems StepOnePlus
Real-Time PCR, Life Technologies, CA, USA), according to
the manufacturer’s instructions.
2.4. Psychodiagnostic Instruments
2.4.1. Hamilton Anxiety Rating Scale (HAM-A). The
Hamilton Anxiety Rating Scale (HAM-A) revised version
questionnaire consists of 14 items used to define several
anxiety-related symptoms, including both psychological
and somatic symptomatology. The 14 items included are as
follows: anxious mood; tension (startles, restlessness, and
crying); fears (dark/strangers/crowds/animals); insomnia;
“intellectual” (poor memory/difficulty concentrating);
depressed mood (including anhedonia); somatic symptoms
(aches, stiffness, and bruxism); sensory (tinnitus, blurred
vision); cardiovascular (e.g., tachycardia and palpitations);
respiratory (chest tightness, choking); gastrointestinal (irrita-
ble bowel syndrome-type symptoms); genitourinary (urinary
frequency, impotence); autonomic (dry mouth, tension
headache), and observed behavior at interview (restless, fidg-
ety, etc.) [27].
In this study, HAM-A was administered by instructed
physicians pre- and posttreatment. To each item, a score
between 0 and 4 was attributed, considering 0 the absence
and 4 the presence of severe symptoms. The total score
ranges from 0 to 56 and was interpreted as follows: <17 mild
anxiety, 17-24 mild-moderate anxiety, and 25-30 moderate-
high anxiety.
Anxious individuals were considered the ones that had a
score equal to or higher than 18 (≥18).
2.4.2. Body Uneasiness Test (BUT). The Body Uneasiness Test
(BUT) is a self-assessment scale used for body image studies
and related pathologies. BUT allows to calculate the Global
Severity Index (GSI) or total average score, which is obtained
from the sum of clinical scores (BUT-A), divided by their
number (34). Item number with score ≥ 1 corresponds to
Positive Symptom Total (PST). The sum of item scores ≥ 1
divided by PST produces the Positive Symptom Distress
Index (PSDI) [31].
Five factors were defined: WP (Weight Phobia), BIC
(Body Image Concerns), A (Avoidance), CSM (Compulsive
Self-Monitoring), and D (Depersonalization). In our study,
we considered as positive for altered perception of body
image a GSI score ≥ 1:2.
2.4.3. Symptom Checklist-Revised (SCL90R). Symptom
Checklist-Revised (SCL90R) is a general psychopathology
self-assessment scale composed of 90 items, which investi-
gates the presence of symptoms in the week before the test
check. These 90 items, which have 5-level Likert answers,
have 10 reference factors: (1) somatization (Som); (2)
obsessive/compulsive (Obs); (3) interpersonal sensitivity
(Interp Sens); (4) Depression (Dep); (5) anxious (Anx);
(6) anger/hostility (Anger Host); (7) phobia (Phob); (8)
psychoticism (Psych); (9) paranoia (Paran); and (10) sleep
disorders. The score goes from 0 to 4, and a score above 1
is an index of pathology [32].
2.5. Composition of Probiotic Oral Suspension (POS). The
POSG received 3 g/day of probiotic oral suspension (POS)
containing Streptococcus thermophiles (1:5 × 1010 colony-
forming unit (CFU), CNCM strain number I-1630), Bifido-
bacterium animalis subsp. Lactis (1:5 × 1010 colony-forming
unit (CFU)), Bifidobacterium bifidum (1:5 × 1010 colony-
forming unit (CFU)), Streptococcus thermophiles (1:5 × 1010
colony-forming unit (CFU)), Lactobacillus bulgaricus
(1:5 × 1010 colony-forming unit (CFU), CNCM strain num-
bers I-1632 and I-1519), Lactococcus lactis subsp. Lactis
(1:5 × 1010 colony-forming unit (CFU), CNCM strain num-
ber I-1631), Lactobacillus acidophilus (1:5 × 1010 colony-
forming unit (CFU)), Lactobacillus plantarum (1:5 × 1010
colony-forming unit (CFU)), Lactobacillus reuteri
(1:5 × 1010 colony-forming unit (CFU), DSM 17938), corn
maltodextrin, anticaking agent (silica), casein, lactose, and
gluten < 3 ppm LLOQ (lower limit of quantitation) (Biocult
Strong, HOMEOSYN, Rome, Italy).
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The placebo was 3 g/day of inert material (flour type 00),
maltodextrin from corn, anticaking agent (silica), casein, lac-
tose, and gluten < 3 ppm LLOQ (lower limit of quantitation)
(HOMEOSYN, Rome, Italy). The appearance of the placebo
was indistinguishable in color, shape, size, packaging, smell,
and taste from that of the probiotic supplement.
2.6. Statistical Analysis. Hardy-Weinberg equilibrium
(HWE) was assessed using SNP-HWE program and tested
using the χ2 analysis (Wigginton et al. 2005). To analyze
the sample, subjects were divided into carriers (IL-1β
rs16944, -598C) and noncarriers (IL-1β rs16944, -598T).
The power of the study was calculated with the Quanto Pro-
gram (USC Biostats, California, US). Shapiro-Wilk test was
performed to determine parametric and nonparametric data.
For comparisons between averages and medians, nonpara-
metric tests for asymmetrically distributed data were con-
ducted in all analyses and presented as mean (±standard
deviation). In order to determine the presence of statistically
significant differences among treatments and IL-1β carriers/-
noncarriers, t-test or Mann–Whitney test was performed.
Percent frequency variation was analyzed using the McNe-
mar and Pearson chi-square test. The association of IL-1β
and the categorical Hamilton score was assessed by binary
logistic regression (LBM) represented as odds ratio (OR)
and 95% confidence intervals (CI). In all the statistical tests
performed, the null hypothesis was rejected at the probability
level greater than or equal to 0.05 (p ≥ 0:05). General Esti-
mated Equations (GEE) were used to model the effects of risk
and protective factor correlation between treatment, A car-
riers and noncarriers, time, and HAM-A results [33]. Statis-
tical analyses were carried out using the IBM SPSS21.0
software for Windows (Armonk, NY: IBM Corp. USA).
3. Results
3.1. Population Characteristics. Out of the 150 patients
recruited, 8 were excluded as they did not meet the inclusion
criteria. The remaining 142 subjects were randomized
equally into two groups. The first group (POSG) consumed
the probiotic mixture formulation, and the second group
(PCG) consumed the placebo formulation. During this clin-
ical trial, 6 subjects from POSG and 34 subjects from PCG
abandoned the study for the poor performances of treat-
ments (Figure 1).
The final sample consisted of 97 patients, with ages rang-
ing from 18 to 62 years old (POSG: mean 43.81 (±14.88),
PCG: mean 32.92 (±11.75)). These patients successfully par-
ticipated and completed the study protocol. At baseline, the
total sample was divided according to A carrier and noncar-
rier for SNP rs16944. The tested SNPs of the IL-1β gene was
in Hardy-Weinberg equilibrium (p > 0:05). The power of the
study was 0.95, with fixed α = 0:05 and 2-sided. Genotype
frequencies shown in TSI population (GG: 0.38, AA: 0.14,
AG: 0.48) [34] are similar to the ones of our subjects (GG:
0.47, AA: 0.14, AG: 0.39), as well as the allele frequencies
for TSI (A: 0.38; G: 0.62) and for our sample (A: 0.34; G:
0.66) (Table 1).
3.2. Influence of IL-1β Polymorphism on HAM-A, BUT, and
SCL-90R Tests. The overall description of the total sample
population at baseline can be seen in Table 2. Of the 65 sub-
jects in POSG, 31 subjects were noncarrier (47.69%) and 34
(52.31%) A carrier. Of the 34 subjects in PCG, 15 (44.12%)
subjects were noncarrier and 19 (55.88%) A carrier. At
baseline, among treatment groups, no statistically significant
difference (p ≥ 0:05) for total BUT score, BUT GSI score,
total SCL-90R score, and SCL90R GSI score (Table 3) was
highlighted. However, at baseline, there is a difference
between frequencies of A carrier and non carrier for
HAM-A within the two groups (p < 0:01) (Table 3). More-
over, A carriers, according to HAM-A, had significantly
higher risk to be anxious compared to noncarriers (p < 0:01;
OR = 5:90 (1.73; 20.16)) (Table 4), showing an interaction
between IL-1β polymorphism and anxiety state. Frequencies
of A carriers and noncarriers, according to psychometric
results, before and after treatment, were reported in Table 5.
3.3. Effect of POS Treatment on HAM-A, BUT, and SCL-90R
Questionnaires according to IL-1β SNP. After 12 weeks of
intervention, we noticed an improvement in the psychomet-
ric parameters according to HAM-A test. POS treatment
reduced score significantly (Table 3) and the frequency of
anxious patients (Δ% = −10:64%), more than in PCG
(Δ% = −5:10%) (Table 5).
Furthermore, GEE analysis highlighted a significant
reduction of the HAM-A total score after POS treatment
compared to the PC (β = −0:33; p < 0:01; OR = 0:68 (0.40;
1.15)). POS treatment determined a significant reduction of
anxiety risk in A carriers (β = −0:32; p = 0:02; OR = 0:73
(0.56; 0.94)), but not in noncarriers (p ≥ 0:05) (Table 6).
These results highlighted the beneficial effect of POS treat-
ment on anxiety state and the increased sensitivity of IL-1β
A carriers to probiotic administration on anxiety reduction.
Conversely, BUT and SCL-90 questionnaire results did not
show significant changes after POS treatment compared to
placebo (Table 3 and Figure 2).
4. Discussion
Among the most prevalent psychiatric disorders, anxiety is a
condition that occurs worldwide, affecting the normal func-
tioning of millions of people and burdening national health
system economies. Despite the worldwide high prevalence,
such disorders are often neglected and misdiagnosed. It is
common for anxiety-affected individuals to be also suffering
from other physical symptoms or concomitant mood disor-
ders, like depressive conditions, drugs abuse, and even sui-
cide (National Institute of Mental Health 2010).
Many studies focused on the role of inflammation on the
CNS functions and relative diseases. In particular, IL-1β has
pleiotropic effects on the CNS, where the proinflammatory
cytokine, released by neurons and glial cells, acts in an auto-
crine and/or paracrine fashion, participates in the onset and
progression of different neurodegenerative diseases and
stroke [16]. Furthermore, proinflammatory cytokine expres-
sion and circulating levels, like interferon gamma (INFγ),
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TNFα, IL-6, and IL-1β, are associated with mood disorder
symptoms [17].
In mouse models, IL-1β concentrations have been linked
not only to neurodegenerative diseases but also to memory
impairment [35] and anxiety disorders [36, 37].
In humans, IL-1β polymorphisms are linked to the levels
of related cytokine expression and consequently to elevated
risk of depression in different populations [25, 26, 28].
Nevertheless, the emerging knowledge of the MGB axis
highlights the role of the gut microbiota as an important
modulator of neuroinflammation, stress response, mood,
and behavior and increases its importance in psychiatric
Table 1: Study population allele and genotype frequencies for IL-1β
rs16944 compared to Tuscan Italians from Southern Europe (TSI).
IL-1β rs16944
Allele frequency A G
TSI 0.38 0.62
Study population 0.34 0.66
Genotype frequency AA AG
TSI 0.14 0.48
Study population 0.14 0.39
CONSORT 2010 flow diagram
Assessed for eligibility (n = 150) 
Lost to follow-up (n = 4)
Discontinued intervention (n = 2)
Lost to follow-up (n = 37)
Discontinued intervention (n = 0)
Analysed (n = 32)
Excluded from analysis (n = 0)
Allocation
Analysis
Follow-up
Randomized (n = 142)
Enrollment
Allocated to intervention PCG (n = 71)
Received allocated intervention (n = 71)
Did not receive allocated intervention (n = 0)
(i)
Excluded (n = 8) 
Not meeting inclusion criteria (n = 8) 
Declined to participate (n = 0)
Other reasons (n = 0)
(i)
(ii)
(iii)
(ii)
Allocated to intervention POSG (n = 71)
Received allocated intervention (n = 71)
Did not receive allocated intervention (n = 0)
(i)
Analysed (n = 65)
Excluded from analysis (n = 0)(i) (i)
(ii)
Figure 1: Study design. Consort flow diagram of the study. Probiotic oral suspension group (POSG) and placebo control group (PCG).
Table 2: Descriptive characteristics of recruited study population.
Parameter
(n = 97) Mean (±SD)
Gender (%)
Female = 61:9%
Male = 38:1%
Age 41.29 (±14.90)
Total BUT score 37.17 (±33.36)
BUT GSI score 1.09 (±0.98)
Total SCL-90R score 61.83 (±47.33)
SCL-90R GSI score 0.69 (±0.53)
Hamilton score 10.91 (±7.31)
Descriptive table. Results are expressed in mean ± SD. BUT: Body
Uneasiness Test (BUT); SCL90R : Symptom Checklist-Revised; HAM-A:
Hamilton Anxiety Rating Scale.
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Table 4: IL-1β A carrier risk for depression, dysmorphic, and anxiety symptoms.
χ2 value χ2p β SE p OR (minimum-maximum) R2
BUT 1.91 0.17 0.92 0.67 0.17 2.50 (0.67; 9.31) 0.06
SCL-90R 1.63 0.20 0.97 0.78 0.21 2.64 (0.58 12.09) 0.06
HAM-A 9.08 <0.01 1.78 0.63 <0.01 5.90 (1.73; 20.16) 0.18
IL-1β A carrier risk for depression, dysmorphic, and anxiety symptoms evaluated with Body Uneasiness Test (BUT), Symptom Checklist-Revised (SCL90R),
and Hamilton Anxiety Rating Scale (HAM-A).
Table 5: BUT, SLC-90R, and HAM-A frequencies.
BUT SCL-90 HAM-A
Healthy Dysmorphic symptoms Healthy Depressive symptoms Healthy Anxiety symptoms
A carrier
Total population
T0 54.55% 45.45% 68.18% 31.82% 56.76% 43.24%
T1 61.54% 38.46% 66.67% 33.33% 70.97% 29.03%
Δ% -6.99% 1.52% -14.21%
PCG
T0 100.00% 0.00% 100.00% 0.00% 37.50% 62.50%
T1 100.00% 0.00% 100.00% 0.00% 50.00% 50.00%
Δ% 0.00% 0.00% -12.50%
POSG
T0 47.37% 52.63% 63.16% 36.84% 62.07% 37.93%
T1 58.33% 41.67% 63.64% 36.36% 78.26% 21.74%
Δ% -10.96% -0.48% -16.19%
Noncarrier
Total population
T0 75.00% 25.00% 85.00% 15.00% 88.57% 11.43%
T1 88.89% 11.11% 87.50% 12.50% 93.10% 6.90%
Δ% -13.89% -2.50% -4.53%
PCG
T0 100.00% 0.00% 100.00% 0.00% 100.00% 0.00%
T1 100.00% 0.00% 100.00% 0.00% 100.00% 0.00%
Δ% 0.00% 0.00% 0.00%
POSG
T0 70.59% 29.41% 82.35% 17.65% 86.21% 13.79%
T1 83.33% 16.67% 80.00% 20.00% 91.30% 8.70%
Δ% -12.75% 2.35% -5.10%
Total
Total population
T0 64.29% 35.71% 76.19% 23.81% 72.22% 27.78%
T1 64.29% 35.71% 76.19% 23.81% 81.67% 18.33%
Δ% 0.00% 0.00% -9.44%
PCG
T0 100.00% 0.00% 100.00% 0.00% 64.29% 35.71%
T1 100.00% 0.00% 100.00% 0.00% 71.43% 28.57%
Δ% 0.00% 0.00% -7.14%
POSG
T0 58.33% 41.67% 72.22% 27.78% 74.14% 25.86%
T1 66.67% 33.33% 68.75% 31.25% 84.78% 15.22%
Δ% -8.33% 3.47% -10.64%
Frequencies for positive/negative classification on depression, dysmorphic, and anxiety symptoms evaluated with Body Uneasiness Test (BUT), Symptom
Checklist-Revised (SCL90R), and Hamilton Anxiety Rating Scale (HAM-A). Results are expressed as percentage. POSG: psychobiotic oral suspension group;
PCG: placebo control group.
Table 6: Association of IL-1β and POSG treatment with HAM-A results.
β Error SD p OR (minimum-maximum)
POSG vs. PCG -0.33 0.11 <0.01∗ 0.68 (0.40; 1.15)
POSG vs. PCG in IL-1β rs16944 noncarriers -0.29 0.19 0.12 0.75 (0.52; 1.08)
POSG vs. PCG in IL-1β rs16944 A carriers -0.32 0.13 0.02∗ 0.73 (0.56; 0.94)
HAM-A results associated with polymorphism rs16944 within the IL-1β gene with 12 weeks in the psychobiotic oral suspension group (POSG). GEE analysis
for HAM-A results, significant values (∗p ≤ 0:05) are expressed for POSG vs. placebo control group (PCG), POSG vs. PCG in IL-1β rs16944 noncarrier group,
and POSG vs. PCG in IL-1β rs16944 carrier group.
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disorder onset and progression, including anxiety [14, 15,
19, 21]. The gut microbiota is able to regulate systemic
IL-1β concentrations [38], potentially modulating anxiety
disorders [39–41].
Despite the numerous studies, the mechanism that links
systemic inflammation and neurological disorders is still
poorly understood, and nowadays, there is a gap in the scien-
tific literature about the role of IL-1β in human anxiety.
In this study, we genotyped the IL-1β gene (rs16944) to
observe the relationship of the polymorphism and anxiety
state in an Italian population sample. At baseline, we found
frequency differences between IL-1β A carriers and noncar-
riers, according to HAM-A scores (p < 0:01). In fact, anxious
subjects were 43.24% A carriers and 11.43% noncarriers. At
baseline, A carriers had moderate but significative increased
risk to be anxious compared to noncarriers (5.90 (1.73;
20.16)).
Our observations implicate a bidirectional relationship
between anxiety disorders and rs16944 polymorphism in an
Italian population. The present results are in line with
previous data shown by Kovacs et al. [29], which found a
relationship between high life stress and anxiety symptoms,
measured by the Brief Symptom Inventory, and the minor
A allele of rs16944 polymorphism in Hungarian population.
In that study, however, the increase in anxiety symptoms was
related to childhood adversity, suggesting that both early life
stress and the presence of the minor allele A are synergic con-
tributing factors in disorder development. The number of
studies investigating the role of IL-1β SNPs in anxiety disor-
ders is few; hence, the present results should stimulate scien-
tific interest on the influence of genetic asset and anxiety
disorders.
In the light of this association, we investigated the com-
bined effect of IL-1β polymorphism and probiotic adminis-
tration in mood disorder phenotypes. Logan and Katzman
assumed for the first time that the use of probiotics as
adjuvant treatment in patients with major depressive disor-
der, a condition with complex pathophysiology associated
with neurotransmitter and neuromodulator deficiencies,
increased proinflammatory cytokine levels, gastrointestinal
disturbances, and HPA axis dysfunction [42]. More recently,
literature has shown that selective modulation of gut micro-
biota by exogenous agents, such as probiotic administration,
could represent a novel therapeutic approach for mood and
anxiety disorders [43, 44]. The beneficial effects of anxiety-
and depression-related behavior are mainly obtained
through the administration of the genera Bifidobacterium
and Lactobacillus, but only some specific strains have
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ensured positive results [15]. Therefore, the secondary out-
come of the present study was to evaluate the potential anxi-
olytic effect of the novel psychobiotic formulation to treat or
prevent anxiety disorders, assessed with HAM-A scale,
according to the IL-1β SNP rs16944.
After the 12-week intervention, we observed an
improvement in the psychometric parameters. As deter-
mined by GEE analysis, HAM-A total score was signifi-
cantly reduced in subjects who consumed the probiotic
formulation (p < 0:01) compared to PCG results. Further-
more, the probiotic mixture lowered the percentage of anx-
ious patients (Δ% = −10:64%), more than in PCG
(Δ% = −5:10%) (Table 5).
These data suggest that probiotic intake has an impact on
anxiety and confirmed our previous results of the concomi-
tant administration of probiotics and hypocaloric diet in
obese subjects [45] that suggested a greater improvement of
anxiety symptoms.
For the evaluation of body image perception, BUT-A was
performed both at baseline and on follow-up visit. As can be
observed in Table 3, at baseline, BUT did not highlight a dif-
ference between POSG and PCG GSI score results
(1:19 ± 1:02 and 0:52 ± 0:31, respectively), regardless of
being A carrier or noncarrier. At the end of the 12-week
intervention, we did not notice a significant reduction in
BUT-A GSI in both POS and PC groups. Thus, we cannot
conclude that the administered probiotic formulation is able
to modify body image disorders. Moreover, our results are
not in line with a previous study performed by De Lorenzo
et al. [46], probably because the groups selected in that study
included only women, making it difficult to compare the
results, knowing the test’s limitation according to Cuzzolaro
et al. [31] in the male population. Therefore, in contrast to
Messaoudi et al. [47], our GSI results of psychological distress
measured by SCL-90R after 12-week intervention were not
significant (p ≥ 0:05) in this study. In our opinion, those
results can be explained by the low GSI score (GSI < 1) since
the baseline time point (Table 3).
Family environment and genetics are established risk fac-
tors in the etiology of psychiatric disorders as well as anxiety
development [48]. Multiple genes of small effect contribute
to the disorder vulnerability, and the interaction between
genetic and distressing environmental factors may lead to
the onset of anxiety disorders [49]. There is a number of con-
vincing studies that have recognized a direct transmission of
anxiety within families, mainly observed in first-degree rela-
tives, with an overall four- to sixfold increased risk [50]. The
genetic contribution to the pathophysiology of psychiatric
disorders is highly complex. Previous studies found higher
risk of depression in IL-1β gene rs16944 carriers of the higher
synthesizing A allele, in schizophrenia [25] and Alzheimer
disease patients [26].
Interestingly, in this study, after the 12-week probiotic
intake, IL-1βA carriers, but not noncarriers, had a significant
reduction of HAM-A score (p = 0:02), and the frequency per-
centage of anxious carriers has been cut from 37.93% to
21.74% (Table 5). Although we cannot exclude an indepen-
dent impact of the minor A allele of rs16944 on microbiota
composition and modulation, our results suggest that the
psychobiotic administration determined a reduction of anxi-
ety and related symptoms and restored psychological equilib-
rium in the treated sample.
In conclusion, despite the limitations related to the lack
of IL-1β blood level measurement in this clinical study, our
results suggest that the consumption of probiotics mitigates
anxiety symptoms, especially in healthy adults with the
minor A allele of rs16944 as a risk factor. This study provides
further evidences that gut microbiota is involved in the psy-
chological state and that its modulation may improve the
overall quality of life. Furthermore, the 12-week intervention
was sufficient to afford significant results without manifesta-
tion of adverse events, and so, the psychobiotic intake repre-
sents a good approach to attenuate anxiety-related feelings.
Thus, probiotics might serve as a new therapeutic approach
for neuropsychiatric disorder treatment and/or prevention.
Although preclinical data suggest the benefits of probiotic
use in anxiety-related disorders, clinical evidence is some-
what lacking as well as the establishment of which probiotic
strains clearly have psychobiotic properties. In the light of
these observations, clinical studies on the role of psychobio-
tics in anxiety are at the very least necessary in order to estab-
lish more accurately the probiotic therapeutic efficiency.
The research field related to gut microbiota manipulation
and mood disorders is far from exhausted. Hence, our results
are aimed at further contributing to the scientific evidences
on psychobiotic ability to manage anxiety disorders and
improve related symptomatology and identifying the poten-
tial mechanisms implicated. The next step would be the
assessment of the minor A allele of rs16944 on microbiota
composition and modulation and then the “psychobiotics”
effect of probiotics compared to anxiolytic drugs on
anxiety-diagnosed subjects, to further confirm their psycho-
tropic properties.
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